The initial success of the copyright undeniably revolutionized the pharmaceutical landscape, but investing in companies strongly reliant on off-patent versions presents a uncertain picture. While early returns were impressive, the expiration of patents and the appearance of less expensive alternatives have eroded sales. Thus, a thorough assessment